Products Recommend
Plasauto∑
Plasma filter (OP-03,OP-05,OP-08)
Double plasma filter (EC-20,30,40,50)
PLASORBA BR
IMMUSORBA PH
IMMUSORBA TR
ACF CUREFLO
REXEED-A
REXEED-L
Dialysis System MDS-101
Location：Home >> ProductsProducts

IMMUSORBA PH


Indication

Autoimmune diseases (e.g., Systemic lupus erythematosus, Malignant rheumatoid arthritis, Guillain-Barré syndrome, Chronic inflammatory demyelinating polyneuropathy, Multiple sclerosis)

Features of IMMUSORBA PH-350(L)

  • Therapeutic plasmapheresis by removing pathogenic substances from patient's plasma by selective adsorption.
  • No need for the replacement of plasma, minimizing the risk of infection with hepatitis, AIDS, etc.
  • Applicable to patients with protein allergy.

Performances

Plasma samples were collected at the inlet and outlet of the column.

Data: Kamifukuoka Sogo hospital, Seisuikan Hospital

Ohashi et al. Jpn J Apheresis 13(2) : 201-202, 1994

Blood samples for removal rate were collected before and after treatment.

Data: Kamifukuoka Sogo hospital, Seisuikan Hospital

Plasma samples were collected at the inlet and outlet of the column.

Okudaira et al. Therapeutic Plasmapheresis Ⅳ, 149-152, 1984

Clinical course

In this case, a 48-year-old female with a 5-year-history of RA (stage 3, class 3), experienced relief from joint pain and the disappearance of rheumatoid nodules. The clinical improvements accompanied with the shown laboratory findings, which were maintained for over 3 months.

RAHA : Rheumatoid arthritis hemagglutination assay
IC : Immune complexes

Kobayashi et al. Therapeutic Plasmapheresis Ⅳ, 153-157, 1984


Specifications

IMMUSORBA PH-350 (L) specifications

Immunoadsorption Column

Adsorbent Material Phenylalanine immobilized polyvinylalcohol gel
Volume 350 mL
Priming Volume 300 mL
Container Material Polypropylene
Dimension 211mm[L] x 62mm[D]
Weight 650 g
Sterilization High pressure steam

Particle Removal Filter

Filter Material Polyethylene (coated with ethylene-vinylalcohol copolymer)
Area 0.07 m2
Container Material Poly (vinyl chloride)
Dimension 165mm[L] x 22mm[D]
Priming Volume 30 mL
Sterilization Ethylene oxide

Caution

For patients undergoing treatment with angiotensin-converting enzyme (ACE) inhibitor, there is a possibility that treatment with the IMMUSORBA PH-350 will lead to a drop in blood pressure. Simultaneous treatment with ACE inhibitor and the IMMUSORBA PH-350 must be avoided.
The IMMUSORBA PH-350 is intended for the treatment of plasma. Never run whole blood through the IMMUSORBA PH-350. Thrombocytes cannot pass through the IMMUSORBA PH-350 and may cause blockage.
Do not use IMMUSORBA PH-350 with plasma containing a large amount of thrombocytes.


Featured References
Hirata et al.
IMMUSORBA TR and PH.
Ther Apher Dial. 7:85-90, 2003.
Yoshida et al.
IMMUSORBA TR and IMMUSORBA PH: Basics of design and features of functions.
Ther Apher. 4:127-34, 2000.
References
Gaubitz et al.
Prospective randomized trial of two different immunoadsorbers in severe systemic lupus erythematosus.
J Autoimmun. 11:495-501, 1998.
Yoshida et al.
IMMUSORBA TR and IMMUSORBA PH: Basics of design and features of functions.
Ther Apher. 4:127-34, 2000.
Yang et al.
Plasma adsorption in critical care.
Ther Apher. 6:184-8, 2002.
Hirata et al.
IMMUSORBA TR and PH.
Ther Apher Dial. 7:85-90, 2003.
Sugimoto et al.
Immunoadsorption plasmapheresis using a phenylalanine column as an effective treatment for lupus nephritis.
Ther Apher Dial. 10:187-92, 2006.
Yamaji et al.
Long-term clinical outcomes of synchronized therapy with plasmapheresis and intravenous cyclophosphamide pulse therapy in the treatment of steroid-resistant lupus nephritis.
Ther Apher Dial. 12:298-305, 2008.
Loo et al.
Immunoadsorption and plasmapheresis are equally efficacious as adjunctive therapies for severe lupus nephritis.
Transfus Apher Sci. 43:335-40, 2010.